- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Nasdaq
Wall Street JournalEN
L
LEGN
Legend Biotech Corp
18.12
-0.24-1.31%After Hours: 18.12 0.00 0.00%16:10 02/20 EST
OPEN/PREV CLOSE18.33/18.36
TODAY RANGE17.97-18.54
VOL1.36M
MARKET CAP3.35B
52 WEEK RANGE16.24-45.30
AVG VOL (3M)2.60M
% TURNOVER0.74%
TURNOVER--
P/E (TTM)-13.9181
% RANGE3.05%
EPS(TTM)-1.3019
P/E(FORWARD)-11.4684
P/B3.309
BVPS5.48
DIVIDEND--
P/S5.31
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.30B
SHARES OUTSTANDING184.69M
NEXT EARNINGS03/09-03/13
FREE FLOAT182.28M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
How New FDA Myeloma Guidance and Board Refresh May Shape Legend Biotech’s (LEGN) Risk‑Reward Profile
Simply Wall St·4d ago
Assessing Legend Biotech (LEGN) Valuation After FDA Draft Guidance Favors CARTITUDE 6 Trial Design
TipRanks·02/12 11:46
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Simply Wall St·02/09 16:18
How Legend Biotech’s Boardroom Shake-Up and New Audit Chair Will Impact Legend Biotech (LEGN) Investors
Simply Wall St·02/07 13:11
Legend Biotech (LEGN) Valuation Check As Board Changes And CARVYKTI Sales Update Draw Attention
Reuters·02/06 21:00
Legend Biotech beruft Gareth Kung in den Vorstand
Reuters·02/06 21:00
Legend Biotech Appoints Gareth Kung to Board and Audit Committee Chair
Simply Wall St·02/06 10:17
Why Investors Shouldn't Be Surprised By Legend Biotech Corporation's (NASDAQ:LEGN) 26% Share Price Plunge
Dow Jones·02/04 14:37
Legend Biotech Is Maintained at Overweight by Barclays
Dow Jones·02/04 14:37
Legend Biotech Price Target Cut to $80.00/Share From $90.00 by Barclays
Benzinga·02/04 14:27
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $80
Reuters·02/04 11:16
LEGEND BIOTECH <LEGN.O>: BARCLAYS CUTS TARGET PRICE TO $80 FROM $90
TipRanks·02/04 10:50
Legend Biotech price target lowered to $80 from $90 at Barclays
Same Industry
Name/Symbol
Change%
Price